A molecular staging protocol using reliable markers is of importance in predicting the prognosis of patients with non-small cell lung cancer (NSCLC) and for instituting their appropriate post-surgical treatment. We analysed tumor tissues from 187 NSCLC patients. The DNA and mRNA were extracted from frozen specimens, and then polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exons 5 ± 8, and mutations of K-ras at exon 1. To determine MRP-1/CD9 gene and KA11/CD82 gene expression, which have been postulated to be metastasis suppressor genes, we have applied quantitative RT ± PCR. A Cox multivariate regression analysis showed that nodal status, MRP-1/CD9 and K-ras status were signi®cant factors for prognosis (P50.0001, P=0.0083 and P=0.0004, respectively). Based on these results, we classi®ed the patients into three groups according to their MRP-1/ CD9 and K-ras status. Patients with both MRP-1/CD9 positive and wild K-ras tumors were de®ned as group A, patients with either reduced MRP-1/CD9 or mutant Kras tumors were de®ned as group B and patients with both reduced MRP-1/CD9 and mutant K-ras tumors were designated as group C. This new classi®cation was signi®cantly correlated with the tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). The overall survival rate of the group A patients was signi®cantly better than the group B patients (59.6% vs 27.9%, P=0.0001) and also that of group B patients was better than the group C patients (27.9% vs 20.0%, P=0.0378). This tendency was also found in patients with 110 node-negative NSCLCs (A vs B vs C=75.8% vs 34.9% vs 0.0%, P50.0001). A Cox multivariate regression analysis in NSCLC patients demonstrated that an evaluation for both MRP-1/CD9 expression and K-ras mutations had a signi®cant prognostic eect as well as nodal status (P50.0001).
Introduction
Lung cancer remains the leading cause of death due to cancer in Japan. The overall 5-year survival of patients with NSCLCs has been reported to be no more than 12%, and surgical resection remains the best form of treatment for NSCLC when the tumor is localized in the pulmonary parenchyma (Bains, 1991) . However, many of these patients will go on to suer from local and/or distant disease relapses that require other treatment modalities. Even in resected stage I lung cancers, primary tumor relapses still occur in almost 30% of the patients (Bains, 1991; Mountain, 1997) . Under these circumstances, it seems justi®ed to reevaluate the classi®cation of the diseases with an early recurrent probability. To date, the staging of lung cancer has been essentially based on cumulative survival statistics, and the anatomic and morphological criteria are used to determine the stage groupings (Mountain, 1997) . However, the focus pertaining to factors of potential prognostic utility has recently turned to the expression of molecular markers (Masters et al., 1996) . Several genetic alterations, such as the activation of oncogenes or the inactivation of tumor suppressor genes are frequently observed in NSCLC (Masters et al., 1996; Sundaresan et al., 1995) . These genetic alterations are considered to be essential for the process of carcinogenesis and a few have been reported to be associated with a poor prognosis for NSCLC (Slebos et al., 1990; Rosell et al., 1993; Mitsudomi et al., 1993; Greenblatt et al., 1994) . Mutations in the K-ras and p53 genes have been suggested to indicate a poor prognosis for NSCLS patients (Slebos et al., 1990; Rosell et al., 1993; Mitsudomi et al., 1993; Greenblatt et al., 1994) . About 15 ± 24% of lung adenocarcinomas have been reported to contain mutations of K-ras at codons 12 and 13, which were associated with a shorter survival (Slebos et al., 1990; Rosell et al., 1993) . In contrast, mutations in the p53, one of the most commonly detected genetic alterations in many human cancers, may also be of prognostic importance in patients with lung adenocarcinoma (Mitsudomi et al., 1993; Greenblatt et al., 1994; Huang et al., 1998) . Mutations in p53 have been reported to occur in 31 ± 55% of NSCLCs, and most of them are detected in the region between exons 5 and 8 (Greenblatt et al., 1994) .
Previously we have established a murine monoclonal antibody (MAb), M31-15, which inhibits cell motility by recognizing motility related protein-1 (MRP-1) (Miyake et al., 1991) . Transfection with human MRP-1/CD9 cDNA revealed that cell motility and growth were suppressed in the MRP-1/CD9-expressing cells (Ikeyama et al., 1993) . In addition, studies with mouse melanoma BL6 cells demonstrated that the metastatic potential of all transformants expressing MRP-1/CD9 was lower than that of the parent BL6 cells (Ikeyama et al., 1993) . Recently, it has been reported by another laboratory that the MRP-1/CD9 gene was more highly expressed in the primary colon cancer as compared to its corresponding metastatic tumor using dierential display cloning (Cajot et al., 1997) . Moreover, we revealed that reduced MRP-1/ CD9 expression was associated with a poor prognosis in patients with breast cancers and NSCLCs Higashiyama et al., 1995) . In addition, as part of our evaluation of the members of the transmembrane 4 superfamily (TM4SF) as possible prognostic predictors, we have also found that reduced KAI1/CD82 gene expression was a poor prognostic factor for patients with NSCLCs (Adachi et al., 1996) . This gene, which is identical to CD82, suppresses tumor metastasis in prostate cancer, and its decreased expression may be involved in malignant progression (Dong J-T et al., 1995) .
Therefore, of the many genetic markers for prognosis in NSCLCs, MRP-1/CD9 and KA11/CD82 gene expression, as well as p53 and K-ras mutations may have signi®cant value as prognostic indicators. In particular, the simultaneous evaluation of multiple genetic markers is of cardinal importance. Although the standard TNM staging protocols are quite useful, in combination with the molecular markers, they will greatly increase in value for de®ning the roles of primary and adjuvant therapy, especially in those patients who are destined for early disease recurrence and require adjuvant therapy. In the present study, we investigated in the same cohort which factors and which combinations of these factors had the most signi®cant eect on predicting the prognosis and the new staging classi®cation of NSCLC patients.
Results
Relationship between p53, K-ras mutations and known prognostic factors
Based on PCR ± SSCP analysis, of 187 primary NSCLCs studied, 65 carcinomas (34.8%) had mutations of p53 and only 15 carcinomas (8.0%) had K-ras mutations. These 65 cases with a mutant p53 gene and 15 with a mutant K-ras gene were also analysed by DNA sequencing (Table 1 ). All of mutant p53 cases had point mutations and three cases with non-missense mutations were detected. Of 114 adenocarcinomas of the lung, 27 tumors (23.7%) had mutations in p53 and 12 tumors (10.5%) had mutations in K-ras. Of 62 squamous cell carcinomas, 29 cases (46.8%) had mutations, in p53, and only two cases (3.2%) had mutations in K-ras. Of 11 large cell carcinomas, nine cases (81.8%) had mutations in p53, and only one case (9.1%) had a mutation in K-ras. In addition, 31 tumors (16.6%) out of the 187 NSCLCs had mutations in exon 5 of p53, but only one tumor had a mutation in exon 6 of p53. Sixteen tumors (8.6%) had mutations in exon 7 of p53, and 17 tumors (9.1%) had mutations in exon 8 of p53. Of 130 smoking patients with NSCLCs, mutations in p53 were found in 48 patients (36.9%) and mutations in K-ras were detected in 12 patients (9.2%). Of 57 non-smoking patients with NSCLCs, only 17 patients (29.8%) had mutations in p53, whereas three patients (5.3%) had mutations in K-ras.
There were no statistically signi®cant correlations between mutations of these genes and their smoking habits, the patient's age at surgery, gender, tumor status, nodal status, pathological stage or tumor grade.
In contrast, p53 mutation was signi®cantly associated with the tumor histology; the p53 mutation rate was signi®cantly lower in adenocarcinomas than that in squamous cell carcinomas (23.7% vs 46.8%, P50.0001) and the rate in squamous cell carcinomas was in turn signi®cantly lower than that in large cell carcinomas (46.8% vs 81.8%, P50.0001). No significant relationship was found between the distribution of mutant exons of the p53 gene and other prognostic factors.
Relationship between MRP-1/CD9, KAI1/CD82 gene expression and known prognostic factors Of 187 primary NSCLCs studied, 108 (57.7%) were evaluated as MRP-1/CD9 gene positive and 79 (42.3%) as having reduced gene expression (Figure 1 ). There were no statistically signi®cant correlations (w 2 ) between MRP-1/CD9 gene expression and the patients' age at surgery, gender, tumor histology or tumor grade. In contrast, MRP-1/CD9 expression was strongly associated (Mann ± Whitney's U test) with the tumor status (P=0.0016), and pathological stage (P50.0001), and had a slight tendency to be associated with nodal status (P=0.0651). On the other hand, 39 carcinomas (20.9%) were evaluated as KAI1/CD82-positive and 148 tumors (79.1%) were designated as negative (Figure 1) . No statistically signi®cant correlations were also found between KAI1/CD82 gene expression and the patients age at surgery, gender, tumor histology or tumor grade. AD  AD  AD  SQ  AD  AD  AD  AD  SQ  SQ  SQ  AD  LA  SQ  SQ  AD  SQ  AD  AD  AD  SQ  AD  LA  SQ  AD  SQ  AD  AD  AD  AD  AD  SQ  AD  AD  LA  AD  AD  AD   2  2  3  2  3  2  2  2  2  2  2  4  1  1  2  3  1  1  3  3  1  1  2  2  1  2  2  2  2  3  3  2  1  1  1  2  3  3  4  2  2  2  3  3  3  2  2  1  2  2  1  4  1  2  2  2  3  4  3  1  2  1  2  2  1  1  1  2  2  2  2  3  4 Association of p53 and K-ras mutations and MRP-1/ CD9 and KAI1/CD82 gene expression with the overall survival of NSCLC patients
There was no signi®cant dierence in overall survival between patients with wild-type p53 and those with mutant p53 (48.9% vs 37.1%). In contrast, patients with wild-type K-ras had a signi®cantly better survival rate than those with mutant K-ras (47.0% vs 30.0%; P=0.0369). The overall survival rate of patients whose tumors were positive for MRP-1/CD9 gene expression was strikingly higher than that of patients with MRP-1/CD9-reduced tumors, as described previously (57.6% vs 25.9%, P=0.0001). This dierence was particularly evident in patients with N0 nodal status (84.5% vs 58.5%, P=0.0050). The overall survival rate for patients with KA11/CD82-positive tumors was significantly better than that of individuals whose tumors had reduced KAI1/CD82 gene expression; the overall survival rate of 39 patients with KAI1/CD82-positive tumors was 68.4%, whereas the survival rate of 148 patients with reduced expression was 38.4% (P=0.0024). To evaluate the potential prognostic factors for NSCLC, the Cox regression analysis was performed as shown in Table 2 . Only three variables, K-ras status, MRP-1/CD9 status and nodal status, were found to be signi®cant factors for prognosis (P=0.0004, P=0.0083 and P50.0001, respectively).
A novel classi®cation of NSCLC patients according to MRP-1/CD9 gene expression and K-ras mutations
Since the evaluation for both MRP-1/CD9 gene expression and K-ras gene status was considered to be useful for the prognosis of patients with NSCLCs, we classi®ed them into three groups according to their MRP-1/CD9 gene expression and K-ras gene status.
Patients with both MRP-1/CD9 positive and wild Kras tumors were de®ned as group A, patients with either reduced MRP-1/CD9 or mutant K-ras tumors were de®ned as group B and the patients with both reduced MRP-1/CD9 and mutant K-ras tumors were designated as group C (Table 3) . Group A consisted of 98 patients, group B of 84 patients, and group C of ®ve patients. In group B patients, 74 had reduced MRP-1/ CD9 and wild K-ras tumors, whereas only ten patients had MRP-1/CD9 positive and mutant k-ras tumors. This new classi®cation was associated with tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). However, no statistically signi®cant relationships were found between this new classi®cation and gender, age, nodal status, histologic type, smoking or tumor grade.
Correlation between the prognosis and the novel classi®cation according to MRP-1/CD9 gene expression and K-ras mutations
In NSCLC patients, the overall survival rate of group A patients was signi®cantly better than that of group B patients (59.6% vs 27.9%, respectively, P=0.0001) and also that of group B patients was better than that of group C patients (27.9% vs 20.0%, respectively, P=0.0378) (Table 3, Figure 2a ). Of the group C patients, 2 patients had T3N0M0 diseases, one patient T4N0M0 disease, one patient T4N2M0 disease and the other had T1N2M0 disease. Node positive two patients underwent mediastinal radiotherapy (50 Gy in 25 fractions for a period of 5 weeks) after surgical resection and then were treated by two cycles of adjuvant chemotherapy including cisplatin (80 mg/m 2 given intravenously on day 1), doxorubicin (40 mg/m 2 given intravenously on day 1) and vindesine (3 mg/m 2 given intravenously on day 1, 8 and 15). The others had no postoperative chemotherapy and radiotherapy before recurrence. Four patients died due to brain metastases, who were treated by whole brain radiation.
Only one patient with T1N2M0 disease is alive for 43.1 months, but has bone metastasis. In addition, of 110 node-negative patients, the overall survival rate of group A with both normal genes was signi®cantly better than that of group B patients who had either abnormal one (75.8% vs 34.9%, respectively, P=0.0002), and also there was a signi®cant dierence between group B patients and group C patients (34.9% vs 0.0%, respectively, P50.0001) (Figure 2b ). The Cox multivariate regression analysis in NSCLC patients is shown in Table 4 . An evaluation for both MRP-1/CD9 expression and K-ras mutations was found to be the signi®cant prognostic factor as well as nodal status Table 4 (gender, age at surgery, smoking, T status and tumor grade) did not correlate with the MRP-1/CD9 and Kras gene status or its prognostic value. Moreover, this double evaluation was the most useful prognostic factor in adenocarcinomas and squamous cell carcinomas, followed by the nodal status (P=0.0018 and P=0.0397).
Discussion
As previously reported, a reduction of MRP-1/CD9 gene expression in NSCLCs was associated with a poor prognosis (Higashiyama et al., 1995) . The link between reduced MRP-1/CD9 expression and a poor prognosis was independent of nodal status, age at surgery, tumor grade or gender. This MRP-1/CD9 reduction was strongly associated with an increased risk of recurrence, especially in patients with N0 status and with stage I diseases, which may suggest that node-negative patients with reduced MRP-1/CD9 gene expression may already have occult systemic diseases. In NSCLC patients, the Cox regression multivariate analysis indicated that positive MRP-1/CD9 gene expression was better correlated with the overall survival than KAI1/CD82 and p53 mutations except for K-ras mutation.
In contrast, KAI1/CD82 gene expression in NSCLCs was also correlated with the tumor status, nodal status and pathological stage, and reduced KAI1/CD82 gene expression was inversely correlated with the overall survival rate as described previously (Adachi et al., 1996) . However, KAI1/CD82 gene expression was a weak indicator of survival as compared with MRP-1/ CD9 gene expression. With respect to the progression of lung cancer, the reduction of KAI1/CD82 gene expression might occur at an earlier stage than the MRP-1/CD9 gene reduction, because we have identi®ed only a few cases with MRP-1/CD9 reduced tumors which had KAI1/CD82 positive expression, whereas almost half of the cases with KAI1/CD82 reduced tumors had positive MRP-1/CD9 expression. These results agreed well with our previous immunohistochemical study (Huang et al., 1997) , and suggested that even in the early stages of NSCLC, the expression of the KAI1/CD82 gene might already be diminishing and thus a large number of patients with early stage NSCLC might already have systemic diseases. Therefore, the Cox regression model indicated that KAI1/ CD82 positivity was much less reliable for the prognosis of patients with NSCLCs than MRP-1/ CD9 positivity (P=0.2138 and P=0.0083, respectively).
On the other hand, several studies have assessed the use of mutations in the p53 genes as a prognostic factor for NSCLC (Mitsudomi et al., 1993; Greenblatt et al., 1994) , but these results still remain controversial (Lee et al., 1995) . As our results indicated, 65 carcinomas had mutations in p53, but no signi®cant dierence was found in the overall survival between those patients with mutations in p53 and those with Abbreviations: Group A, both MRP-1 positive and K-ras wild group; Group B, either MRP-1 reduced or K-ras mutant group; Group C, both MRP-1 reduced and K-ras mutant group; NR, not reached wild-type p53. The Cox regression analysis also showed that p53 mutations were not signi®cant prognostic factors for survival as compared with other variables, such as K-ras gene mutations and MRP-1/CD9 gene states.
Most point mutations in the K-ras gene in human lung cancers consist of guanine to thymine transversions in codon 12 of exon 1. Tumors which acquired a K-ras mutation in vitro were reported to become more resistant to radiation and several drugs (Sklar, 1988) . Some studies have shown that a K-ras mutation was a strong predictive factor indicating a poor prognosis for lung cancer (Slebos et al., 1990; Rosell et al., 1993) which coincided with our results. However, K-ras mutations are not frequently detected in NSCLCs, and were found in less than 7% of NSCLCs in Japan (Fukuyama et al., 1997) ; this is also in agreement with our results. A dierence in racial genetics may be one of the possible reasons for this variable incidence. Therefore, the presence of a K-ras mutation alone may not be very useful for the discrimination of patients who are at high risk for early disease recurrence in Japan. Indeed, our results suggested that a K-ras gene mutation was almost speci®c for adenocarcinomas, and was one of the signi®cant prognostic factors for a poor survival outcome. Nevertheless, it is essential to evaluate K-ras mutations in combination with other genes, such as MRP-1/CD9, in reliably predicting a prognosis for NSCLC patients.
Of these genetic alterations, the MRP-1/CD9 gene expression and K-ras gene status were two of the more useful predictors for the prognosis of NSCLC patients. In addition, we demonstrated that we can predict the prognosis of patients with NSCLC more precisely by simultaneously evaluating both MRP-1/CD9 gene status and K-ras gene mutations. The evaluation for both MRP-1/CD9 expression and K-ras mutations could identify node-negative NSCLC patients who are at high risk for early disease recurrence. The Cox regression multivariate analysis indicated that an evaluation for both MRP-1/CD9 and K-ras gene status was the best predictor of the overall survival. Since the number of patients with K-ras mutations have been reported to be much larger in Europe and North America than in Japan (Slebos et al., 1990; Rosell et al., 1993) , this evaluation might be more useful in those continents. In combination with the molecular staging according to MRP-1/CD9 and K-ras gene status, the standard TNM staging protocols will greatly increase in value for de®ning not only the roles of primary and adjuvant therapy, but also the application of surgery for the patients with advanced stage diseases. When samples obtained by mediastinal lymph node biopsy have both MRP-1/CD9 positive and wild K-ras gene, these tumors may be evaluated to be low grade of malignancy and aggressive surgery with chemo-radiation therapy may be recommended even if they are patients with N2 or N3 status.
In addition, MRP-1/CD9 and K-ras gene may be used for gene therapy of patients with NSCLCs. Adenovirus vectors have the ability to transduce postmitotic cells and have a higher achievable titers (Curiel et al., 1996) . For example, p53 gene has been studied extensively to restore the growth abnormalities of a cancer cell to normal cell. In a recent phase I trial, nine patients with relapsed NSCLC with p53 mutations were treated with direct local injections of viruscontaining wild-type p53 (Roth et al., 1996) . There was documented tumor regression in three patients and stable disease in three other patients. On a theoretical basis, if MRP-1/CD9 are reintroduced back into the appropriate lung cancer cells, there would be metastasis suppression of the tumors and aggressive surgery may be recommended. Furthermore, the antisense technology may downregulate the mutant oncogene expression; K-ras gene in antisense orientation was used to transduce human lung cancer cell lines using a retroviral vector (Zhang et al., 1993) . In summary, recent remarkable progress in molecular biology has led to the elucidation of many events involved in the process of malignant transformation (Masters et al., 1996) , and molecular and biological markers have been identi®ed to serve as predictors of survival. These markers may also be used to categorize patients more accurately for staging. The development of more accurate indicators for predicting the prognosis may serve to further de®ne the roles of primary and adjuvant therapy, especially in those patients who are destined for early disease recurrence and require adjuvant therapy. In addition to K-ras gene mutations and reduced MRP-1/CD9 gene expression, the combination of these and other markers such as antigenic changes of the major blood group ABH antigens (Miyake et al., 1992) which were suggested to be indicators for prognosis for squamous cell carcinoma, could allow for a re®nement of the classi®cation of lung cancer, thereby approaching the ideal of a more precise molecular classi®cation that might provide a ®rm basis for therapeutic decisions in the clinical setting. Further investigation and prospective trials are necessary to con®rm the predictive value of these markers, and to assess their usefulness as staging tools. for a period of 5 weeks) for microscopic-positive margins. We detected distant metastases in 85 patients during observation period and among these 85 patients, 21 patients had also local recurrence. Seven patients had only locoregional recurrence.
Materials and methods

Patients and tumor specimens
In order to ascertain the presence of cancer cells, 6 mm thick frozen sections were cut on a cryostat and were immediately stained with hematoxylin and eosin. After the connective tissues were dissected away, the other half of a given tumor specimen containing cancer cells more than 80% of all tissue cells was then selected and stored at 7808C for subsequent DNA and RT ± PCR analysis. Genomic DNA was extracted from these specimens by proteinase K digestion, followed by phenol/chloroform extraction and ethanol precipitation (Sambrook et al., 1989) . The total cellular RNA was puri®ed from fresh or frozen tumor tissues by the acid guanidine thiocyanate procedure (Chomczynski and Sacchi, 1987) .
PCR ± SSCP and DNA sequencing
The following oligonucleotides were synthesized as partially intron-based PCR primers of p53 and K-ras as described previously (Hongyo et al., 1995) . Forty cycles of PCR ampli®cation were performed as follows: denaturation at 948C for 1 min, annealing at 608C for 1 min for exons, 5, 6 and 7 of p53; at 558C for exon 8 of p53, and at 508C for exon 1 of K-ras, and then extension at 728C for 1.5 min followed by a ®nal extension at 728C for 7 min. Seven ml of the PCR products were diluted with 10 ml of a buer consisting of 20 mM EDTA, 96% deionized formamide and 5 mg/ml Dextran Blue 2000. Heat denaturation was performed at 958C for 5 min, and then the solution was placed on ice for 5 min. Electrophoresis was then performed at 188C for 3 h for exon 5 of p53 and exon 1 of K-ras, and for 2.5 h for exons 6, 7 and 8 of p53. The gel was stained with ethidium bromide and visualized under ultraviolet light.
In order to ascertain the presence of base changes, direct sequencing was performed using a chemiluminescent DNA sequencing kit (Toyobo, Osaka, Japan). Biotinylated primers of each exon were synthesized for end-labeling.
RT ± PCR analysis
First strand cDNA synthesis was performed with total RNA using a cDNA synthesis kit (Pharmacia, Piscataway, NJ, USA) following the manufacturer's protocol. In order to obtain reproducible quantitative performance for the RT ± PCR assay for MRP-1/CD9 and KAI1/CD82, we titrated the amount of starting cDNA against the number of ampli®cation cycles. All subsequent assays were carried out using the parameters that yielded ampli®cation of MRP-1/CD9, KAI1/CD82 and b-actin DNA (the internal control) within a linear range. The primers used in this study have been previously described (Higashiyama et al., 1995; Adachi et al., 1996; Nakajima-Iijima et al., 1985) . The reaction mixture was subjected to 25 PCR amplification cycles of 40 s at 948C, 40 s at 608C and 90 s at 728C, and the same PCR conditions were used to amplify the bactin DNA. Tubes containing all ingredients except templates were included in all runs and served as negative reaction controls. Preparations of the MRP-1/CD9-and KAI1/CD82-positive human endothelial cell line, ECV304 were used as positive controls (Takahashi and Sawaski, 1992) . The ampli®ed DNA samples were run on a 1% agarose gel, and the bands were visualized with ethidium bromide and photographed with a Polaroid camera. Band quanti®cation was performed using densitometry. The densitometric values obtained for MRP-1/CD9 and KAI1/ CD82 of a given tumor sample were divided by the corresponding b-actin value, and were referred to as the gene expression ratio for each gene. The expression ratio of the tumor was then divided by that of ECV304, in order to obtain the gene conservation rate for each gene (Higashiyama et al., 1995; Adachi et al., 1996) . Tumors with values 41.0 conserved (positive) gene expression, whereas those with values of 41.0 were considered to have reduced (negative) gene expression.
Statistical analysis
The overall cancer-speci®c survival was de®ned from the date of the operation to the date of death due to cancer. Smokers were de®ned as patients with a Brinkman index greater than 400. Dichotomous variables were analysed with Pearson's chi-square test. Mann-Whitney's U test was used to compare interval variables. The Kaplan-Meier method was used to estimate the probability of overall survival as a function of time (Kaplan and Meier, 1958) , and dierences in the survival of subgroups of patients were compared with Mantel's log-rank test (Mantel, 1966) . Multivariate analyses for survival were performed using the Cox regression model (Cox, 1972) . All P values were based on two-tailed statistical analysis, and a P value 50.05 was considered to indicate statistical signi®cance.
